A5071499842- Neurological disorders and treatments
- Parkinson's Disease Mechanisms and Treatments
- Botulinum Toxin and Related Neurological Disorders
- Genetic Neurodegenerative Diseases
- Glycogen Storage Diseases and Myoclonus
- Neurological and metabolic disorders
- Parkinson's Disease and Spinal Disorders
- Neurological diseases and metabolism
- Trigeminal Neuralgia and Treatments
- Obsessive-Compulsive Spectrum Disorders
- Epilepsy research and treatment
- Autism Spectrum Disorder Research
- Neuroscience and Neuropharmacology Research
- Genetics and Neurodevelopmental Disorders
- Metabolism and Genetic Disorders
- Dysphagia Assessment and Management
- Restless Legs Syndrome Research
- Neurogenetic and Muscular Disorders Research
- Autoimmune Neurological Disorders and Treatments
- Nuclear Receptors and Signaling
- Lysosomal Storage Disorders Research
- Intracranial Aneurysms: Treatment and Complications
- Hereditary Neurological Disorders
- Biochemical and Molecular Research
- Pharmacological Effects and Toxicity Studies
University of Buenos Aires
2013-2025
Ecological Society of America
2023
Hospital de Clínicas "José de San Martín"
2011-2021
Pontificia Universidad Católica del Ecuador
2017
Military University Nueva Granada
2017
Novartis (Switzerland)
2012-2016
Hospital Civil de Guadalajara
2016
Hospital Español
2016
Boehringer Ingelheim (India)
2016
Hospital Británico de Buenos Aires
2016
To describe the clinical features, etiology, findings from neuroimaging, and treatment results in a series of 29 patients with Holmes tremor (HT).
Abstract Botulinum toxin (BT) therapy is a complex and highly individualised defined by treatment algorithms injection schemes describing its target muscles their dosing. Various consensus guidelines have tried to standardise improve BT therapy. We wanted update by: (1) Acknowledging recent advances of algorithms. (2) Basing dosing tables on statistical analyses real-life data 1831 injections in 36 different 420 dystonia patients 1593 31 240 spasticity patients. (3) Providing more detailed...
We examined basal and reflex salivary flow rate composition in 46 patients with Parkinson's disease (PD), both off on conditions, compared to 13 age-matched controls without underlying or treatment affecting autonomic function. Whole saliva was collected 12 hours after withdrawal of dopaminergic drugs at the peak levodopa-induced motor improvement. Twenty-three PD had received domperidone a week before study. Basal significantly lower state (P<0.005). Levodopa increased (P<0.05)...
This study investigated the long-term safety of rivastigmine (12 mg/d capsules, 9.5 mg/24 h patch) and effects on motor symptoms in patients with mild-to-moderately severe Parkinson disease dementia.This was a 76-week, prospective, open-label, randomized aged 50 to 85 years. Primary outcomes included incidence of, discontinuation due to, predefined adverse events (AEs) potentially arising from worsening capsules. Secondary frequency AEs/serious AEs. Efficacy Alzheimer's Disease Cooperative...
Cinnarizine and flunarizine are selective calcium blockers that have been used to treat prevent vertigo. We studied 15 patients who had extrapyrqmidal syndromes after taking these drugs. Eleven parkinsonism, one with persistent akathisia as well; an orofacial tremor; one, acute alone; dystonic reaction. All but improved when the drug therapy was discontinued. Seven were also depressed during treatment. must therefore be added list of potentially risky drugs known induce extrapyramidal...
Botulinum toxin has been thoroughly studied as a potential tool in the treatment of several pain syndromes. Therefore, we assessed clinical effects botulinum type A injections 12 patients with otherwise unresponsive idiopathic trigeminal neuralgia. Patients were infiltrated 20-50 units trigger zones. Those who presented mandibular involvement also masseter muscle. The on weekly basis using Visual Analogic Scale for pain. Ten our reported significant benefit from injections, reduction or even...
Abstract Background: Perampanel is a selective, noncompetitive α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole‐propionic acid receptor antagonist. Two multicenter randomized, double‐blind, placebo‐controlled, parallel‐group phase III studies assessed the efficacy and safety of adjunctive perampanel in patients with Parkinson's disease motor fluctuations. Methods: In both (301 302), levodopa‐treated were randomized treated once‐daily oral placebo (n = 504), 2 mg 509), or 4 501). The primary end point...
Age and sex are known risk factors for Parkinson's Disease (PD), but it remains controversial if there differences in the diagnosis latency. The objective of this study was to examine these Latin America. American Research Consortium on Genetics PD (LARGE-PD) includes patients from countries across America who were diagnosed using UK Brain Bank criteria. Ages at onset (AAO; N = 2,792), (AAD; 1,416), calculated latency (N 1,416) extracted LARGE-PD database compared both males females overall,...
Summary: Eight cases of diurnal bruxism (DB) secondary to long-term antidopaminergic drug exposure are reported. Five exhibited a grinding pattern, one clenching form, and two mixed type. An odontological etiology was absent throughout. EMG recordings disclosed distinct patterns muscle activity, with brief rhythmic, forceful contractions the other featuring sustained prolonged contractions. Surface EEG monitoring during 24-h period confirmed absence sleep. Several trials failed provide...
Over the last few years, cases of movement disorders induced by flunarizine and cinnarizine have been increasingly reported. We describe a series 101 patients, whose ages ranged from 37 to 84 years (mean 69.1), developing abnormal movements frequently associated with depression, secondary treatment either or both drugs. Symptoms closely resembled those neuroleptic drugs remitted on drug discontinuance in all but five after 5-22 months' follow-up. Whether not such undesirable side effects are...
Abstract The common belief that primary dystonia is a purely motor disorder with no anatomical substrate and other accompanying neurological dysfunction has recently been challenged. In addition, there increasing evidence the basal ganglia besides control, plays role in cognitive functioning. However, systematic performance evaluation carried out patients blepharospasm (BS), one of most forms adult dystonia. We evaluated series 20 BS group 17 controls matched by severity mood symptoms, age,...
Abstract To determine whether the immediate response to electrode implantation (micro lesion effect, MLE) in internal segment of globus pallidus (GPi) predicts symptom improvement with deep brain stimulation (DBS) at 6 months patients Parkinson's disease (PD) or generalized dystonia. Electrode subthalamic nucleus (STN) prior electrical has been reported predict a beneficial effect DBS PD, but this is also case for GPi either PD dystonia not established. We studied 20 (11 and 9 dystonia) who...
Objectives. To determine the prevalence of weight loss (WL) in PD patients, its relationship to severity motor manifestations and appetite changes. Methods. 144 patients 120 controls were evaluated a single session. All subjects asked about changes body appetite. examined with UPDRS-III Hoehn Yahr (HY) scales. Subscores tremor, bradykinesia /rigidity, non-dopaminergic symptoms (NDS) analyzed individually. Multivariable logistic regression analysis was used an association between WL...
Botulinum toxin is a well-known therapy for patients with diverse movement disorders. Its application has been extended to other Here, we document the case of 70-year-old man hemifacial spasm associated trigeminal neuralgia secondary an ectatic basilar artery. He was treated botulinum type A, 2.5 mouse units over five sites at orbicularis oculi and one buccinator muscle. After injections, relief gained not only from twitching but also pain. When effects vanished, spasms pain recurred....
Mutations in Leucine-Rich Repeat Kinase 2 (LRRK2), primarily located codons G2019 and R1441, represent the most common genetic cause of Parkinson's disease European-derived populations. However, little is known about frequency these mutations Latin American In addition, a prior study suggested that LRRK2 polymorphism (p.Q1111H) specific to Latino Amerindian populations might be risk factor for disease, but this finding requires replication. We screened 1734 patients 1097 controls enrolled...
✓ Camptocormia is a well-known feature in cases of Parkinson disease (PD), and usually unresponsive to dopaminergic therapy. A 62-year old man with long history PD severe progressive camptocormia underwent bilateral pallidal stimulation. During the next 6 months sustained improvement trunk flexion was observed. After 14 follow up, patient's almost normal.